Altimmune (ALT) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
0 of 1 scored quarter beat.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 20268-K, before open · 7:30 am ET | −0.13 | −0.15 | −13.2% | 1,750.00 | $0.00 | −100.0% | −16.6%release day |
| Aug 12, 20268-K, before open · 7:33 am ET | — | −0.12 | — | — | $0.00 | — | −2.3%release day |
| May 13, 20268-K, before open · 7:34 am ET | — | −0.18 | — | — | $0.00 | — | −1.9%release day |
| Nov 6, 20258-K, before open · 7:04 am ET | — | −0.21 | — | — | $5,000.00 | — | +5.1%release day |
| Aug 12, 20258-K, before open · 7:10 am ET | — | −0.27 | — | — | $5,000.00 | — | +7.1%release day |
| May 13, 20258-K, before open · 7:04 am ET | — | −0.26 | — | — | $5,000.00 | — | −4.2%release day |
| Feb 4, 2025 E | — | −0.33 | — | — | $5,000.00 | — | —estimated date |
| Nov 12, 20248-K, before open · 7:09 am ET | — | −0.32 | — | — | $5,000.00 | — | +29.1%release day |
Estimate-vs-actual scoring began Oct 2026 and is still accruing: 1 of the 8 quarters above carries a scored estimate. We never backfill an estimate we didn't observe.
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
Estimates for this company are reported in its local currency, while the annual actuals behind the fiscal-year figures are in US dollars. A year-ago figure and the estimate beside it would be two different currencies there, so we withhold those cells rather than publish a comparison that is not like for like. Where a year-ago figure is still shown, it is on the same local-currency basis as the estimate beside it, not a dollar one. The estimate rows are the provider's own figures, unconverted.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 4 | 3 | 5 | 7 |
| Avg estimate | −0.17 | −0.16 | −0.61 | −0.67 |
| Low estimate | −0.21 | −0.17 | −0.68 | −0.90 |
| High estimate | −0.15 | −0.14 | −0.56 | −0.55 |
| Year-ago EPS | — | −0.18 | — | −0.61E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 9 | 9 | 6 | 6 |
| Avg estimate | 1,750.00 | 18.5M | 1,875.00 | 25.7M |
| Low estimate | 1,750.00 | 18.5M | 1,875.00 | 25.7M |
| High estimate | 1,750.00 | 18.5M | 1,875.00 | 25.7M |
| Year-ago revenue | — | 0.00 | — | — |
| Implied growth | — | — | — | — |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.17 | −0.16 | −0.61 | −0.67 |
| 7 days ago | −0.16 | — | −0.58 | −0.64 |
| 30 days ago | −0.16 | — | −0.58 | −0.64 |
| 60 days ago | — | — | — | — |
| 90 days ago | — | — | — | — |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved −0.16 → −0.17 over 39 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were Altimmune's latest quarterly earnings?
Altimmune reported diluted EPS of −0.15 and revenue of $0.00 on Nov 12, 2026.
How did Altimmune's stock move after its last earnings report?
Altimmune moved −16.6% in the session after its Nov 12, 2026 report.

